Non-alcoholic fatty liver disease historical perspective: Difference between revisions
No edit summary |
|||
| Line 7: | Line 7: | ||
==Historical Perspective== | ==Historical Perspective== | ||
*First introduced in 1980, NAFLD is a quite new concept. <ref name="pmid28507929">{{cite journal |vauthors=Vizuete J, Camero A, Malakouti M, Garapati K, Gutierrez J |title=Perspectives on Nonalcoholic Fatty Liver Disease: An Overview of Present and Future Therapies |journal=J Clin Transl Hepatol |volume=5 |issue=1 |pages=67–75 |year=2017 |pmid=28507929 |pmc=5411359 |doi=10.14218/JCTH.2016.00061 |url=}}</ref> | |||
*It is divided into non-alcoholic fatty liver (NAFL) and non-alcoholic steatohepatitis (NASH) primarily based on histologic findings. | |||
*Biopsies of NAFL may also display macrovesicular steatosis with lobular and periportal irritation however do now not display cellular injury and fibrosis (steatohepatitis), which characterizes NASH. <ref name="pmid28297791">{{cite journal |vauthors=Zhao ZH, Liu XL, Fan JG |title=[Research on the natural history of non-alcoholic fatty liver disease should be taken seriously] |language=Chinese |journal=Zhonghua Gan Zang Bing Za Zhi |volume=25 |issue=2 |pages=81–84 |year=2017 |pmid=28297791 |doi= |url=}}</ref> | |||
*NAFL has in large part been taken into consideration benign, but recent cohort studies display a high hazard for development to NASH in as much as 44% on serial biopsies at 5 years. | |||
*NASH reasons modern fibrosis which could result in cirrhosis and hepatocellular cancer (HCC). | |||
==References== | ==References== | ||
Revision as of 21:07, 7 December 2017
|
Non-Alcoholic Fatty Liver Disease Microchapters |
|
Differentiating Non-Alcoholic Fatty Liver Disease from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case studies |
|
Non-alcoholic fatty liver disease historical perspective On the Web |
|
American Roentgen Ray Society Images of Non-alcoholic fatty liver disease historical perspective |
|
FDA on Non-alcoholic fatty liver disease historical perspective |
|
CDC on Non-alcoholic fatty liver disease historical perspective |
|
Non-alcoholic fatty liver disease historical perspective in the news |
|
Blogs on Non-alcoholic fatty liver disease historical perspective |
|
Directions to Hospitals Treating Non-alcoholic fatty liver disease |
|
Risk calculators and risk factors for Non-alcoholic fatty liver disease historical perspective |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: Vamsikrishna Gunnam M.B.B.S [2]
Overview
NAFLD/NASH was first described in a 1980 series of obese, non-alcoholic patients of the Mayo Clinic.[1] Since that seminal description, our understanding of NAFLD has progressed minimally. [2]
Historical Perspective
- First introduced in 1980, NAFLD is a quite new concept. [3]
- It is divided into non-alcoholic fatty liver (NAFL) and non-alcoholic steatohepatitis (NASH) primarily based on histologic findings.
- Biopsies of NAFL may also display macrovesicular steatosis with lobular and periportal irritation however do now not display cellular injury and fibrosis (steatohepatitis), which characterizes NASH. [4]
- NAFL has in large part been taken into consideration benign, but recent cohort studies display a high hazard for development to NASH in as much as 44% on serial biopsies at 5 years.
- NASH reasons modern fibrosis which could result in cirrhosis and hepatocellular cancer (HCC).
References
- ↑ Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 1980;55:434-438. PMID 7382552.
- ↑ Day, CP. Non-alcoholic steatohepatitis (NASH): where are we now and where are we going? Gut. 2002 May; 50(5): 585–588.
- ↑ Vizuete J, Camero A, Malakouti M, Garapati K, Gutierrez J (2017). "Perspectives on Nonalcoholic Fatty Liver Disease: An Overview of Present and Future Therapies". J Clin Transl Hepatol. 5 (1): 67–75. doi:10.14218/JCTH.2016.00061. PMC 5411359. PMID 28507929.
- ↑ Zhao ZH, Liu XL, Fan JG (2017). "[Research on the natural history of non-alcoholic fatty liver disease should be taken seriously]". Zhonghua Gan Zang Bing Za Zhi (in Chinese). 25 (2): 81–84. PMID 28297791.